212 related articles for article (PubMed ID: 25020058)
1. The role of cytokines in postmenopausal osteoporosis.
Brincat SD; Borg M; Camilleri G; Calleja-Agius J
Minerva Ginecol; 2014 Aug; 66(4):391-407. PubMed ID: 25020058
[TBL] [Abstract][Full Text] [Related]
2. Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis.
Pacifici R
J Bone Miner Res; 1996 Aug; 11(8):1043-51. PubMed ID: 8854239
[TBL] [Abstract][Full Text] [Related]
3. Experimental techniques for screening of antiosteoporotic activity in postmenopausal osteoporosis.
Satpathy S; Patra A; Ahirwar B
J Complement Integr Med; 2015 Dec; 12(4):251-66. PubMed ID: 26215536
[TBL] [Abstract][Full Text] [Related]
4. Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis.
Seibel MJ; Cosman F; Shen V; Gordon S; Dempster DW; Ratcliffe A; Lindsay R
J Bone Miner Res; 1993 Jul; 8(7):881-9. PubMed ID: 8352070
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of osteoclast activating cytokines, interleukin-11 and transforming growth factor-beta2, as valuable biomarkers for the assessment of bone turnover in postmenopausal osteoporosis.
Shaarawy M; Zaki S; Sheiba M; El-Minawi AM
Clin Lab; 2003; 49(11-12):625-36. PubMed ID: 14651333
[TBL] [Abstract][Full Text] [Related]
6. [Cytokines in bone diseases. Cytokine and postmenopausal osteoporosis].
Inada M; Miyaura C
Clin Calcium; 2010 Oct; 20(10):1467-72. PubMed ID: 20890027
[TBL] [Abstract][Full Text] [Related]
7. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
8. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men.
Riggs BL; Khosla S; Melton LJ
J Bone Miner Res; 1998 May; 13(5):763-73. PubMed ID: 9610739
[TBL] [Abstract][Full Text] [Related]
9. Fluorosis increases the risk of postmenopausal osteoporosis by stimulating interferon γ.
Lv YG; Kang L; Wu G
Biochem Biophys Res Commun; 2016 Oct; 479(2):372-379. PubMed ID: 27644876
[TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
Kassem M
APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
[TBL] [Abstract][Full Text] [Related]
11. [Role of the immune system in the pathophysiology of postmenopausal osteoporosis].
Terauchi M
Nihon Rinsho; 2011 Jul; 69(7):1215-9. PubMed ID: 21774360
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and bone metabolism.
Väänänen HK; Härkönen PL
Maturitas; 1996 May; 23 Suppl():S65-9. PubMed ID: 8865143
[TBL] [Abstract][Full Text] [Related]
13. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
14. Prevention and treatment of osteoporosis with hormone replacement therapy.
Christiansen C
Int J Fertil Menopausal Stud; 1993; 38 Suppl 1():45-54. PubMed ID: 8499959
[TBL] [Abstract][Full Text] [Related]
15. Possible pathogenetic role of new cytokines in postmenopausal osteoporosis and changes during calcitonin plus calcium therapy.
Gür A; Denli A; Nas K; Cevik R; Karakoc M; Sarac AJ; Erdogan F
Rheumatol Int; 2002 Sep; 22(5):194-8. PubMed ID: 12215865
[TBL] [Abstract][Full Text] [Related]
16. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis.
Lindsay R; Nieves J; Formica C; Henneman E; Woelfert L; Shen V; Dempster D; Cosman F
Lancet; 1997 Aug; 350(9077):550-5. PubMed ID: 9284777
[TBL] [Abstract][Full Text] [Related]
17. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
[TBL] [Abstract][Full Text] [Related]
18. Is skeletal responsiveness to thyroid hormone altered in primary osteoporosis or following estrogen replacement therapy?
Langdahl BL; Loft AG; Møller N; Weeke J; Eriksen EF; Mosekilde L; Charles P
J Bone Miner Res; 1997 Jan; 12(1):78-88. PubMed ID: 9240729
[TBL] [Abstract][Full Text] [Related]
19. Overview of osteoporosis.
Riggs BL
West J Med; 1991 Jan; 154(1):63-77. PubMed ID: 2024511
[TBL] [Abstract][Full Text] [Related]
20. Effect of exercise on bone: permissive influence of estrogen and calcium.
Dalsky GP
Med Sci Sports Exerc; 1990 Jun; 22(3):281-5. PubMed ID: 2199749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
